Short Communication:Seminal Reservoirs during an HIV Type 1 Eradication Trial
- 1 September 2005
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 21 (9) , 768-775
- https://doi.org/10.1089/aid.2005.21.768
Abstract
Despite dramatic reduction of the levels of human immunodeficiency virus type I (HIV-1) virions in blood and seminal plasma of infected patients, highly active antiretroviral therapy (HAART) does not eradicate HIV-1. Three patients, with less than 50 copies/ml of plasma viral RNA, were enrolled in this eradication protocol. Didanosine (DDI) and hydroxyurea (HU) were added to their baseline HAART and after a month of therapy, low dose OKT3, followed by a 2-week course of interleukin 2 (IL-2), was administrated. All antiretroviral therapy was then interrupted and the three patients developed viral rebound in the peripheral blood. The V3 loop region of the HIV-1 gp120 from cell-free viral RNA and proviral DNA in blood and seminal compartments was sequenced in one patient. The two major viral isolates in semen cells were macrophage- tropic (R5) and dual-tropic (R5X4), and these isolates were also present in the PBMCs. Six months after the viral rebound, we demonstrated a shift toward dual tropism in semen cell-associated HIV-1 proviral DNA, with the first appearance of a T-lymphotropic (X4) provirus solely in this compartment. The virus responsible for the blood plasma viral rebound was never found in the semen microenvironment. This study suggests viral compartmentalization of the semen microenvironment after an intensification and stimulatory HIV-1 eradication protocol, with evidence of viral evolution.Keywords
This publication has 16 references indexed in Scilit:
- Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivoVirology, 2003
- Intensification and Stimulation Therapy for Human Immunodeficiency Virus Type 1 Reservoirs in Infected Persons Receiving Virally Suppressive Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2002
- Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infectionsAIDS, 2002
- Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapyJournal of Clinical Investigation, 2000
- Residual HIV-1 RNA in Blood Plasma of Patients Taking Suppressive Highly Active Antiretroviral TherapyJAMA, 1999
- Human Immunodeficiency Virus Type 1 in the Semen of Men Receiving Highly Active Antiretroviral TherapyNew England Journal of Medicine, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997
- Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 ReplicationScience, 1994